63; 95% CI 1.06–2.39). There was no differential distribution of cancer of the cervix in PER-exposed or laundry workers. The incidence of malignant melanoma was low in both male and female workers within the two major exposure categories but, based on three incident cases, significantly higher than expected in men exposed to other dry-cleaning agents. Table 3 Cancer morbidity 1985–2006 in a cohort of Swedish dry-cleaners and laundry workers by gender, selected sites and exposure category Site (ICD-7) Males Females PER check details Laundry Othera PER
Laundry Othera Obs SIR (95% CI) Obs SIR (95% CI) Obs SIR (95%
CI) Obs SIR (95% CI) Obs SIR (95% CI) Obs SIR (95% CI) All (140–209) 223 1.11 (0.97–1.26) 100 1.08 (0.88–1.31) 14 1.24 (0.68–2.06) 501 0.91 (0.83–0.99) 260 0.94 (0.83–1.07) 8 0.48 (0.21–0.95) Oesophagus (150) 0 – (0.00–1.51) 0 – (0.00–3.26) 0 – (0.00–26.35) 3 1.25 (0.26–3.65) 2 1.56 (0.19–5.65) 0 – (0.00–46.11) Mitomycin C mouse Liver, gallbladder (155) 8 2.14 (0.92–4.21) 3 1.74 (0.36–5.09) 0 – (0.00–16.77) 10 0.90 (0.43–1.65) 4 0.67 (0.18–1.70) 1 2.81 (0.07–15.63) Lung (162) 23 1.30 (0.82–1.94) 13 1.60 (0.85–2.74) 3 2.95 (0.61–8.62) 35 1.09 (0.76–1.51) 26 1.63 (1.06–2.39) 0 – (0.00–3.55) Breast (170) – – – – – – 140 0.85 (0.72–1.00) 76 0.96 (0.76–1.21) 3 0.63 (0.13–1.85) Cervix (171) – – – – – – 16 1.19 (0.64–1.93) 9 1.45 (0.66–2.75) 1 1.59 (0.04–8.83) Melanoma (190) 5 0.58 (0.19–1.34) 2 0.50 (0.06–1.81) 3 7.04 (1.45–20.58) 9 0.41 (0.19–0.78) 8 0.78 (0.34–1.53) 0 – (0.00–6.36) Other skin (191) 14 1.29 (0.70–2.16) 5 1.00 (0.32–2.33) 0 – (0.00–5.76) 13 0.71 (0.38–1.22) 5 0.51 (0.16–1.19) 0 – (0.00–6.36) Non-Hodgkin’s lymphoma (200, 202) 15 2.02 (1.13–3.34) 8 2.33 (1.01–4.59) 0 – (0.00–9.46) 18 1.14 (0.68–1.81) 8 0.99 (0.43–1.95) 0 – (0.00–7.53) Hodgkin’s lymphoma (201) 3 3.22 (0.66–9.40) 0 – (0.00–9.00) 1 23.77 (0.60–132.45) 0 –
(0.00–2.44) 0 – (0.00–5.27) 0 – (0.00–92.22) aSubjects exposed to “other dry-cleaning” While the cohort was defined as those employed in washing establishments between 1973 and 1983 and assembled in 1984, there was a built-in latency between one and 12 years at the start of follow-up in 1985. selleck kinase inhibitor Notably, 35% of the cohort were included already in 1973 and additionally 12% before 1976.